Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylamine SCHEMBL29052258 | 0.96 | SMYD2 (0.35) | SMYD2HTTCYP3A4SMN1; SMN2LTA4H | |
| SCHEMBL706843 | 0.84 | SMYD2 (0.40) | SMYD2HTTCYP3A4SMN1; SMN2LTA4H | |
| SCHEMBL30563707 | 0.82 | SMYD2 (0.36) | SMYD2HTTCYP3A4SMN1; SMN2MAPK1 | |
| SCHEMBL8168666 | 0.82 | SMYD2 (0.36) | SMYD2HTTCYP3A4SMN1; SMN2MAPK1 | |
| SCHEMBL1879760 | 0.82 | SMYD2 (0.36) | SMYD2HTTCYP3A4SMN1; SMN2MAPK1 | |
| SCHEMBL28387134 | 0.82 | TAAR1 (0.38) | SMYD2HTTCYP3A4SMN1; SMN2MAPK1 | |
| SCHEMBL7848052 | 0.82 | SMYD2 (0.36) | SMYD2HTTCYP3A4SMN1; SMN2MAPK1 | |
| SCHEMBL702653 | 0.81 | LTA4H (0.42) | SMYD2HTTCYP3A4SMN1; SMN2LTA4H | |
| SCHEMBL14601099 | 0.81 | SMYD2 (0.34) | SMYD2HTTCYP3A4SMN1; SMN2 | |
| SCHEMBL28549731 | 0.80 | SMYD2 (0.35) | SMYD2HTTCYP3A4SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092777-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | OGEDA SA (BE) | 2019-03-28 | — | — | US | claimed |
| US-10030025-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | OGEDA SA (BE) | 2018-07-24 | — | — | US | claimed |
| EP-2948455-B1 | N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | OGEDA S A (FR) | 2017-09-27 | — | — | EP | claimed |
| EP-3219715-A1 | N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | OGEDA SA (BE) | 2017-09-20 | — | — | EP | claimed |
| US-20170240551-A9 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS | OGEDA SA (BE) | 2017-08-24 | — | — | US | claimed |
| US-20160318941-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS | EUROSCREEN SA (BE) | 2016-11-03 | — | — | US | claimed |
| WO-2000050478-A1 | NOVEL FORMULATIONS OF ALKYLLITHIUMS WITH IMPROVED THERMAL STABILITY, PROCESSES TO PRODUCE THESE FORMULATIONS AND PROCESSES FOR USING THE SAME TO IMPROVE STABILITY OF LIVING POLYMER CHAIN ENDS | FMC CORPORATION (US) | 2000-08-31 | — | — | WO | claimed |
| EP-1023333-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 2000-08-02 | — | — | EP | claimed |
| WO-1999012979-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 1999-03-18 | — | — | WO | claimed |
| US-20260118791-A1 | TONER | CANON KK (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4086705-B1 | TONER | CANON KK (JP) | 2026-03-25 | — | — | EP | disclosed |
| EP-4012501-B1 | EXTERNAL ADDITIVE FOR TONER, TONER AND IMAGE FORMING APPARATUS | CANON KK (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-12487539-B2 | Fine particle, external additive for toners, and toner | CANON KABUSHIKI KAISHA (JP) | 2025-12-02 | — | — | US | disclosed |
| US-20250334892-A1 | FINE POWDER FOR TONER AND TONER | CANON KK (JP) | 2025-10-30 | — | — | US | disclosed |
| EP-0974582-B1 | Process for the preparation of 4-substituted azetidinone derivatives | TAKASAGO PERFUMERY CO LTD (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-6340751-B1 | REACTION OF IMIDAZOLONE WITH AMIDE AND MAGNESIUM COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-22 | — | — | US | disclosed |
| WO-2000050478-A1 | NOVEL FORMULATIONS OF ALKYLLITHIUMS WITH IMPROVED THERMAL STABILITY, PROCESSES TO PRODUCE THESE FORMULATIONS AND PROCESSES FOR USING THE SAME TO IMPROVE STABILITY OF LIVING POLYMER CHAIN ENDS | FMC CORPORATION (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-1023333-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 2000-08-02 | — | — | EP | disclosed |
| EP-0974582-A1 | Process for the preparation of 4-substituted azetidinone derivatives | Takasago International Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
| WO-1999012979-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240551-A9 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS | GPR3, ACKR3, KCNK3 | SMYD2 4392/4885HTT 4852/4885CYP3A4 990/4885 |
| US-20160318941-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS | GPR3, ACKR3, KCNK3 | SMYD2 4392/4885HTT 4852/4885CYP3A4 990/4885 |
| US-10030025-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | GPR3, ACKR3, KCNK3 | SMYD2 4392/4885HTT 4852/4885CYP3A4 990/4885 |
| US-20260118791-A1 | TONER | MSR1, H1-2, TAAR1 | SMYD2 3442/4885HTT 1951/4885CYP3A4 1965/4885 |
| US-20190092777-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | PKD1, GPR3, FFAR3 | SMYD2 4630/4885HTT 3918/4885CYP3A4 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.